• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Segment 8 - Treatment's Financial Constraints

Article

The panelists discuss clinicians and their perspectives on financial constraints in treatment of NSCLC.

The panelists discuss clinicians and their perspectives on financial constraints in treatment of NSCLC.

Dr Sugarbaker says of the 4 major cancers ̶ including lung, breast, colon and prostate ̶ lung cancer is by far the number one killer, especially in women. For NSCLC, conversations between providers and payers need to focus on where multi-modality treatment makes sense for certain patients.

Dr Langer comments that increasingly, insurers will approve 1 maintenance drug or another, but not 2. This is largely driven by cost concerns. Even will oral agents, costs are still exorbitant. It can be difficult to find or offer financial support for patients.

Dr Sugarbaker adds that the progress that is been made in NSCLC depends on treatment. “You can’t evaluate new therapies without coverage for particularly protocol therapies.” He says the “onus” is on insurers and managed care organizations to continue supporting innovative therapies in a protocol setting because that is how they have made and will continue to make progress.

Related Videos
Phaedra Corso, PhD, associate vice president for research at Indiana University
Julie Patterson, PharmD, PhD
Nancy Dreyer, MPH, PhD, FISE, chief scientific advisor to Picnic Health
Seth Berkowitz, MD, MPH, associate professor of medicine, University of North Carolina at Chapel Hill
Inma Hernandez, PharmD, PhD, professor at the University of California, San Diego Skaggs School of Pharmacy and Pharmaceutical Sciences
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
Dr Julie Patterson, National Pharmaceutical Council
Shawn Tuma, JD, CIPP/US, cybersecurity and data privacy attorney, Spencer Fane LLP
Leslie Fish, PharmD.
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.